Announcement PDF Microba Life Sciences Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Microba Life Sciences Limited ABN: 82 617 096 652 Reporting period: For the year ended 30 June 2026 Previous period: For the year ended 30 June 2025 2. Results for announcement to the market $ Revenues from ordinary activities down 5.8% to 14,758,461 Loss from ordinary activities after tax attributable to the owners of Microba Life Sciences Limited up 38.7% to (20,721,356) Loss for the year attributable to the owners of Microba Life Sciences Limited up 38.7% to (20,721,356) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $20,721,356 (30 June 2025: $14,939,471). 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security 0.18 1.57 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declared during the current financial period. Previous period There were no dividends paid, recommended or declared during the previous financial period. 7. Dividend reinvestment plans Not applicable. Microba Life Sciences Limited Appendix 4E Preliminary final report 8. Details of associates and joint venture entities Not applicable. 9. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 10. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements have been audited and an unmodified opinion has been issued. 11. Attachments Details of attachments (if any): The Annual Report of Microba Life Sciences Limited for the year ended 30 June 2026 is attached. 12. Signed Signed ___________________________ Date: 31 August 2026 Pasquale Rombola Chair Brisbane Authorised for release by the Board. Microba Life Sciences Limited Corporate directory 30 June 2026 1 Directors Pasquale Rombola Ian Frazer Gene Tyson Jacqueline Fernley Stéphane Chatonsky Executive Key management personnel Luke Reid (Chief Executive Officer) James Heath (Chief Financial Officer) Company secretary James Heath Registered office and Microba Life Sciences Limited principal place of business Level 10 324 Queen Street Brisbane QLD Australia Share register Automic Pty Ltd Level 35 477 Collins Street Melbourne VIC Australia Auditor Pitcher Partners Level 38 345 Queen Street Brisbane QLD Australia Solicitors Thomson Geer Level 28 1 Eagle Street Brisbane QLD Australia Stock exchange listing Microba Life Sciences Limited shares are listed on the Australian Securities Exchange (ASX code: MAP) Website www.microba.com Corporate Governance Statement The Company's corporate governance statement is located at the Company's website: ir.microba.com/corporate-governance/ 4 Expect Better www.microba.com 5 Contents 01 Performance highlights 06 02 Chair, Deputy Chair & CEO Letter 10 03 Operating & Financial Review 13 04 Directors’ Report 29 05 Financial Statements 45 06 ASX Additional Information 96 6 Performance Overview Total revenue with legacy phase-out complete $14.8M Testing revenue growth +92% Number of tests sold (Core test) 22,418 Gross margin, held through transition 47.6% Deferred revenue $1.8M Cash at 30 June 2026 $7.9M ANNUAL REPORT 2026 6 7 Performance Overview Core tests sold by quarter FY26 Revenue transition ($M) Deferred revenue ($M) up 66% Underlying loss after tax ($M) ANNUAL REPORT 2026 7 Underlying loss is a non-IFRS measure; refer to the reconciliation in the Operating and Financial Review. 8 Completed the strategic transition to a focused core testing business • Twelfth consecutive quarter of core testing growth: core testing revenue up 92% to approximately $8.6 million, now the majority of Group revenue, with an exit run-rate above 25,000 tests per annum. • Continuing product revenue grew 53% to $12.7 million while discontinued legacy revenue reduced 72%, completing the planned phase-out and providing a clean revenue base entering FY27. Record volumes in Australia and a scaling enterprise-clinic channel • Microba Microbiome Explorer™ delivered a record Q4 of 5,311 tests, up 54% versus the prior corresponding period (PCP), with 901 ordering clinicians and orders per clinician up 34%. • 43 enterprise-clinic accounts signed since November 2025, selling 5,606 tests, with a key-account pipeline above 175 targets representing estimated ordering potential above 80,000 tests per annum. United Kingdom • Record Q4 of 825 tests, up 92% versus PCP, with 313 active ordering clinicians, up 85%. Own-brand supplements building recurring revenue • PHGG prebiotic fibre unit sales more than doubled to 43,000 units, and the Invivo subscription offering surpassed 1,000 subscribers within its first year. ANNUAL REPORT 2026 Performance Highlights 9 ANNUAL REPORT 2026 Clinical evidence and product leadership • Microba MetaPanel™ clinical validation published in Frontiers in Cellular and Infection Microbiology, reporting greater than 99% median specificity and 91% median sensitivity. • The Phase 1 trial of lead therapeutic asset MAP-315 in ulcerative colitis was provisionally accepted for publication in Nature Communications. • Microba GI Navigator, a new category-defining test powered by the Company’s proprietary Clinical Logic Engine, is on track to launch in October 2026, with the first 35 sales achieved through an early-access program with opinion- leading practitioners across Australia and the United Kingdom. A structurally lower cost base and strengthened capital position • Total operating expenditure down 7% to $29.9 million; cost-streamlining program targeting approximately $7 million per annum of reductions, fully implemented in H1 FY27, supported by AI deployed across customer support, engineering, science and other corporate function teams. • Gross equity proceeds of $13.0 million during FY26 and a further $0.8 million shortly after year end, with strategic partner Sonic Healthcare Limited (ASX: SHL) subscribing for $4.1 million during FY26 placements. • Underlying loss improved 11% to $18.8 million (statutory loss $20.7 million). 10 Microba.com MICROBA LIFE SCIENCES LIMITED | ANNUAL REPORT 2026 01 Chair, Deputy Chair & CEO Letter 11 11 CHAIR, DEPUTY CHAIR & CEO LETTER We remain steadfast in our belief that the human gut microbiome represents one of the biggest untapped opportunities to improve human health, and that microbiome testing will become a routine part of clinical care. FY26 was a defining year for Microba. We removed a range of legacy testing products and services to set the business up around core testing products designed for scale, completed a multi-year product and infrastructure build, and raised the capital to complete the path to cash flow break-even for the whole company. Core testing is now the majority of Group revenue, having been under a third of it two years ago, and we enter FY27 as a clean, focused business with a structurally lower cost base and Microba GI Navigator ready to launch. Microba is creating a new diagnostic category in clinical microbiome testing. Category creation takes time, and our strategy is to de-risk it through a structured, region-by-region market development process aligned to the clinician adoption curve. In Australia, adoption moved beyond innovator clinicians into early adopters during FY26, increasingly characterised by enterprise agreements with healthcare clinics. Australia and the United Kingdom remain the markets in which we are focused and invested. We guided during FY26 to core test volumes above 24,000 and to regional break-even in Australia and the United Kingdom by the end of the year, measured on a regional EBITDA basis. Solid progress was made towards these ambitious targets. Volumes reached 22,418, growth of 78% on FY25 and within 7% of the level guided, and regional break-even was not achieved within the year. The enterprise-clinic channel that now underpins our growth began contracting accounts in November 2025, and those accounts were still maturing at year end. Q4 was a record quarter and a strong finish that carries real momentum into FY27. We exited the year at an annualised run-rate above 25,000 tests, and core testing revenue grew 92% across the year, the Dear Shareholders, compounding result of consistent, disciplined execution as we move up the adoption curve with clinicians in both markets. The statutory loss for the year increased to $20.7 million, from $14.9 million in FY25, primarily reflecting non-cash and non-recurring items in both periods. Excluding those items the underlying loss improved 11%, on operating expenditure down 7%, reflecting disciplined cost management through the year. The Operating and Financial Review sets out the detail and the reconciliation. Microba’s mission to improve human health through microbiome science remains our driving force. During FY26 we continued to demonstrate the clinical utility of our testing, with MetaPanel’s clinical validation published in Frontiers in Cellular and Infection Microbiology and the Phase 1 trial of our lead therapeutic asset MAP-315 in ulcerative colitis provisionally accepted for publication in Nature Communications. Microba GI Navigator, a new category-defining testing product powered by our proprietary Clinical Logic Engine, launches in October 2026. It is the culmination of several years of leadership at the forefront of this new diagnostic category, and it opens our serviceable addressable market to more medical doctors, a significant next segment of the healthcare practitioner market for our tests. GI Navigator is already live with a closed-group early access cohort of opinion-leading practitioners across Australia and the United Kingdom, with the first 35 sales achieved. In therapeutics, six positive sector readouts between November 2025 and July 2026 delivered the efficacy data in chronic disease that prospective partners had been waiting to see. The modality has now been validated. We commenced a formal partnering campaign from July 2026, supported by our Boston-based advisors, with no further research and development investment and our core intellectual property preserved, providing a capital-light path from here. During the year the Company received an inbound approach from a UK-based private equity fund and, after extensive due diligence, agreed in-principle 12 12 CHAIR, DEPUTY CHAIR & CEO LETTER terms, subject to conditions including shareholder approval, for the divestment of our Diagnostics and Supplements businesses at a consideration that would have exceeded the Company’s market capitalisation. The consideration did not change; the final structure did, and when it was no longer in the best interests of shareholders we chose not to proceed. We then moved to secure funding certainty ahead of the Microba GI Navigator launch, completing a $5.0 million placement in June 2026 in which Sonic Healthcare, our largest shareholder and strategic partner, subscribed for $1.5 million. The placement was led by our substantial shareholders investing above their pro rata entitlements, and we are grateful for their support through two capital raisings during the year, and for Sonic’s continued confidence in Microba. Looking ahead, our immediate priorities are clear: launch Microba GI Navigator, grow core testing volumes in Australia and the United Kingdom through the maturing enterprise-clinic channel, realise the full benefit of the cost reductions now in place, and advance our therapeutics partnering campaign. With the core product and platform build substantially complete, our focus in FY27 moves to commercialisation. Together these priorities are directed at a single objective, achieving whole company cashflow break-even, on a run-rate basis, in calendar year 2027, building a self-sustaining business. During the year, as part of the Board’s renewal, Mr Richard Bund and Dr Hyungtae Kim resigned on 19 November 2025 after more than six years of service, and we thank them sincerely for their contribution. Mr Stéphane Chatonsky joined as an Independent Non-Executive Director on 20 November 2025, bringing over 25 years of experience across healthcare, pathology and technology investment. On behalf of the Board, we thank Microba’s employees and partners for their hard work and dedication through a demanding year. We also extend our gratitude to our shareholders for their continued support and belief in Microba’s vision. Yours sincerely, Mr Pasquale Rombola Chair Prof. Ian Frazer (AC) Deputy Chair Dr Luke Reid Chief Executive Officer 13 Microba.com MICROBA LIFE SCIENCES LIMITED | ANNUAL REPORT 2026 02 Operating & Financial Review 14 14 OPERATING & FINANCIAL REVIEW This Operating and Financial Review forms part of, and should be read in conjunction with, the Directors’ Report and the audited financial statements for the year ended 30 June 2026. The financial year ending 30 June 2026 was a year of transition and consolidation for Microba Life Sciences, marked by the completion of the portfolio shift to core testing, the strongest year of core test growth in the Company’s history, and a structurally lower cost base. Financial review 1.Underlying loss is a non-IFRS measure; refer to the reconciliation below. The statutory comparison is affected by one-off items in both years, and the operating cash flow comparison by R&D Tax Incentive receipt timing ($3.1 million received in FY26 versus $6.3 million in FY25). Revenue Revenue from contracts with customers was $14.76 million, down 6% on FY25 ($15.67 million), entirely attributable to the planned phase-out of discontinued legacy products. Continuing product revenue grew 53% to $12.7 million, while discontinuing product revenue reduced 72% to $2.1 million. From Q3 FY26 onwards, reported revenue was no longer affected by legacy roll-off. Core testing revenue grew 92% year-on-year to approximately $8.6 million and represented approximately 62% of Q4 FY26 revenue, up from 31% in Q3 FY25. Core testing volume reached 22,418 tests, up 78% on the 12,629 tests sold in FY25, with the Company exiting FY26 at a rolling-quarter annualised run-rate above 25,000 tests. SUMMARY OF FINANCIAL PERFORMANCE FY26 FY25 CHANGE Total revenue ($m) 14.8 15.7 (6%) Continuing product revenue ($m) 12.7 8.3 +53% Gross margin (%) 47.6 47.5 +0.1pp Total expenses ($m) 29.9 32.2 (7%) Underlying loss after tax ($m) 1 (18.8) (21.2) 11% improved Statutory loss after tax ($m) (20.7) (14.9) (39%) Net operating cash outflow ($m) (12.4) (12.0) (5%) Cash at 30 June ($m) 7.9 11.7 (32%) 15 15 OPERATING & FINANCIAL REVIEW Consistent with Australian Accounting Standards, testing revenue is recognised when the final report is delivered rather than when a kit is ordered and paid for. Microba Microbiome Explorer™ deferred revenue grew 66% to $1.79 million at 30 June 2026, a leading indicator of core testing revenue expected to be recognised in FY27 that grew faster than reported revenue during the year. Recognition of that balance depends on patients returning samples for analysis, and a portion of kits sold is not returned. Performance against FY26 guidance At the FY25 results, and in the FY25 Annual Report, the Company guided to core test volume growth of more than 100% year-on-year, core test volumes above 24,000, and regional break-even in both Australia and the United Kingdom by the end of FY26. Regional break-even was defined on a regional EBITDA basis, excluding corporate costs, product development expenditure and share-based payments, and was forecast to be achieved at test volumes above 24,000 split across the two regions. Substantial progress was made towards these objectives, although they were not fully achieved within FY26. Core test volumes grew 78% to 22,418, within 7% of the guided volume, and regional break-even was not achieved by 30 June 2026. The shortfall reflects the timing of the enterprise-clinic channel ramp described above, which commenced in November 2025 with signed accounts still maturing at year end. At the June 2026 equity raising, the Company replaced the regional break-even measure with a whole-company objective, which is achieving cashflow break-even, on a run-rate basis, in calendar year 2027. The new objective is a broader and more demanding measure, as it includes corporate and product development expenditure that the FY26 objective of regional break-even excluded, and it is supported by the cost reduction program and the revenue and margin drivers set out in this review. 16 16 OPERATING & FINANCIAL REVIEW Gross profit and margin Gross profit was $7.03 million at a gross margin of 47.6% (FY25: $7.44 million and 47.5%). Margin was held broadly stable through the transition year, with the exit of lower-margin distributed and legacy products and growth in own-brand supplements offsetting the revenue mix shift. During the year the Company consolidated its laboratory footprint to achieve economies of scale through its Brisbane based laboratory, revised logistics pathways and made improvements to the kit which improved unit economics with FY27 now set to build on these foundations and to see strong further expansion in both gross profit and gross margins as core testing volumes scale. Operating expenditure Total expenses reduced 7% to $29.92 million (FY25: $32.23 million), reflecting the Q1 FY26 restructuring, the laboratory consolidation, the pause in internal therapeutic development and disciplined cost management, partly offset by a deliberate 79% increase in marketing investment directed at core testing growth and by the non-cash items below. 1. The impairment of $0.75 million relates to testing kit technology associated with the discontinued Invivo EcologiX product range, written down to nil following the Group’s decision to exit the product. EXPENSES FY26 $M FY25 $M CHANGE Employee benefits and related costs 14.35 16.49 (13%) Depreciation and amortisation 4.41 4.43 (0.4%) Other expenses 2.96 3.09 (4%) Consulting fees 1.84 3.42 (46%) Subscriptions and information technology 1.65 1.28 +29% Net foreign currency loss (non-cash) 1.51 - n/a Marketing and advertising 1.18 0.66 +79% Impairment of intangibles 1 0.75 - n/a Research and development 0.42 2.01 (79%) Travel, legal, finance costs and other 0.85 0.84 +1% Total expenses 29.92 32.23 (7%) 17 17 OPERATING & FINANCIAL REVIEW Statutory result and underlying performance The Group recorded a statutory net loss after tax of $20.72 million (FY25: $14.94 million) and a basic loss per share of 3.45 cents (FY25: 3.33 cents). The statutory comparison is significantly affected by non-cash and non-recurring items in both periods: FY25 included a $4.47 million gain on derecognition of contingent consideration and a $1.76 million foreign currency gain, whilst FY26 included a $1.51 million foreign currency loss, a $0.75 million impairment, and a $0.36 million fair value gain on a derivative financial liability. Adjusting for these items, the underlying loss improved 11% year-on-year. 1. Underlying loss is a non-IFRS measure presented to assist shareholders in understanding the performance of the business, is unaudited, and has been prepared consistently for both periods. Cash flow and capital management Receipts from customers were $15.59 million (FY25: $16.95 million), reflecting the legacy revenue phase-out. Net cash used in operating activities was $12.37 million (FY25: $12.01 million), the cashflow comparison is significantly affected by R&D Tax Incentive receipts of $3.06 million in FY26 against $6.31 million in FY25, and excluding grant receipts in both years the underlying operating outflow improved by approximately $2.7 million. The Q4 FY26 operating outflow was 38% below Q4 FY25 on a structurally reduced cost base. Investing outflows of $3.80 million principally comprised $3.67 million of intangible asset payments reflecting the platform build and the development of Microba GI Navigator, which are now substantially complete. The Company completed two equity raisings during FY26 for gross proceeds of $13.0 million, approximately $8.5 million settled in July 2025 completing the June 2025 two-tranche placement, and Tranche 1 of approximately $4.5 million (before costs) of the June 2026 placement at $0.05 per share, in which strategic partner and shareholder Sonic Healthcare Limited (ASX: SHL) subscribed for $1.5 million (before costs) after subscribing for $4.16m in the June 2025 capital raising. During FY26 the Group drew approximately $2.05 million under its Radium Capital R&D Tax Incentive financing arrangements (advances FY26 R&D claim). This was partly offset by $0.67 million of principal repayments on the insurance premium funding (fully repaid during the year) and the equipment finance facility, giving net proceeds from borrowings of $1.39 million. STATUTORY TO UNDERLYING RECONCILIATION FY26 $M FY25 $M Statutory loss after income tax (20.72) (14.94) Impairment of intangibles 0.75 - Net foreign currency loss / (gain) 1.51 (1.76) Fair value gain on derivative financial liability (0.36) - Gain on derecognition of contingent consideration - (4.47) Underlying loss after income tax1 (18.83) (21.17) 18 18 OPERATING & FINANCIAL REVIEW During FY26, following an inbound approach by a UK-based private equity fund, the Company agreed in-principle terms, subject to conditions precedent including shareholder approval, for the divestment of its Diagnostics and Supplements businesses at a consideration that would have exceeded the Company’s market capitalisation. When the final deal structure was no longer in the best interests of shareholders, the Company chose not to proceed. Cash and cash equivalents were $7.95 million at 30 June 2026, and the Company had 700,307,489 fully paid ordinary shares on issue. Going concern and funding The financial statements have been prepared on a going concern basis. The Group incurred a loss of $20.72 million for the year and a net cash outflow from operating activities and lease repayments of $13.31 million, and held cash and cash equivalents of $7.95 million at 30 June 2026. In reaching the going concern conclusion, the Directors had regard to the Group’s demonstrated ability to raise capital and the support of its major shareholders, its continued reliance on the R&D Tax Incentive scheme, its ability to scale back discretionary expenditure to preserve liquidity, and the measures implemented to streamline operations to a lower cost base with the objective of achieving full group cashflow break-even in calendar year 2027. As set out in the financial statements, in the event these initiatives do not materialise as planned, a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern. After assessing forecast cash flows for the twelve months from the date of the report, the Directors concluded there are reasonable grounds to expect the Group will continue as a going concern. Post balance date events On 24 July 2026, shareholders approved the issue of the Tranche 2 placement shares, the share purchase plan shares and attaching options at an Extraordinary General Meeting. On 29 July 2026 the Company issued 8,659,785 Tranche 2 placement shares at $0.05 per share raising approximately $0.4 million before costs, and 8,150,000 share purchase plan shares at $0.05 per share raising approximately $0.4 million before costs, together with 100,004,240 unlisted attaching options exercisable at $0.0625 and expiring three years from issue. On 26 August 2026, the Company announced that it is in preliminary, non-binding discussions with Genetic Signatures Limited (ASX: GSS) regarding a potential merger of the two businesses. The discussions are at an early stage and remain incomplete. No binding agreement has been entered into, no firm decision to proceed has been made by either party, and there is no certainty that any transaction will proceed or as to its terms. Any transaction would be subject to further due diligence and all required regulatory and other approvals. As the discussions are preliminary and incomplete, any financial effect cannot be reliably estimated. No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect, the Group’s operations or state of affairs. Dividends No dividends were paid, recommended or declared during the current or previous financial year. 19 19 OPERATING & FINANCIAL REVIEW Review of Operations & Activities Diagnostics Microba is creating a new diagnostic category in clinical microbiome testing. The Company estimates a future addressable market of $125 billion per annum across seven major markets and 10 indication groups, within which its defined total addressable market is approximately $25 billion per annum, and its serviceable addressable market approximately 18.6 million tests per annum across five focus markets. The Company is derisking this category creation through a structured, region-by-region market-development process aligned to the clinician adoption curve. In Australia, adoption has moved beyond innovators into early adopters, increasingly characterised by enterprise-style contracts with healthcare clinics, in the United Kingdom, clinical testing progressed through the innovator phase with strong adoption signals. Five pillars underpin the growth model, large-scale latent demand, efficient product-accelerated growth engines, essential clinical utility, recurring and sticky revenue, and powerful moats built on proprietary measurement methods, bioinformatics intellectual property, accreditation and a growing clinical-grade dataset. . Five pillars driving durable, scalable, AI-powered growth 001 002 003 Large-scale latent demand Growing clinical evidence is driving acceptance of the microbiome. Clinicians and patients are ready to adopt clinical-grade solutions they can trust. Efficient growth engines A product-accelerated growth model — self-serve signup, always-on funnels, automated lifecycle marketing, AI support — scales beyond a 1:1 sales force. Essential clinical utility A technically rich, self-describing report delivers clear insights and actions, making microbiome testing usable without specialist training. 004 005 Recurring, sticky revenue A technology-led experience supports clinicians and patients from referral to adherence, owning the relationship, lowering CAC and lifting lifetime value. Powerful moats Proprietary measurement methods, bioinformatics IP, accreditation and a growing clinical-grade dataset compound into durable competitive advantage. 20 20 OPERATING & FINANCIAL REVIEW AUSTRALIA: MICROBA MICROBIOME EXPLORER™ Microbiome Explorer delivered successive record quarters through FY26, closing with 5,311 tests in Q4, up 54% versus PCP, an ordering-clinician base of 901 and orders per clinician up 34% versus PCP. The shift to enterprise-style clinic accounts changed the shape of the business in FY26 with 43 accounts signed from November 2025, together selling over 5,600 tests and representing estimated ordering potential above 24,000 tests per annum, with the broader key-account pipeline exceeding 175 targets and estimated ordering potential above 80,000 tests per annum. This channel supports accelerating revenue, improved sales efficiency and a more predictable, recurring revenue base as accounts mature, while increasing customer concentration and extending payment terms. 21 21 OPERATING & FINANCIAL REVIEW UNITED KINGDOM: MICROBA MICROBIOME EXPLORER™ FY26 was the first full year of UK market access. Building on the Invivo Healthcare customer base, adoption continued to track ahead of the Australian curve at the equivalent time post launch, with a record Q4 of 825 tests, up 92% versus PCP, and 313 active ordering clinicians, up 85%. Essentials and Extended variants were introduced into the UK market and broadened the range, and all legacy UK testing products were discontinued during the year. MICROBA METAPANEL™ In partnership with Sonic Healthcare, focus remained on gastroenterology specialists and key opinion leaders, with 225 tests sold in Q4 FY26 and full-year volumes broadly stable. Clinical validation published in Frontiers in Cellular and Infection Microbiology (greater than 99% median specificity, 91% median sensitivity) is expected to support routine adoption over time. PRODUCT DEVELOPMENT DRIVING CLINICIAN ADOPTION Through FY26 Microba released features advancing clinical utility and workflow integration, including the Oral Species biomarker, Practitioner Pays, Pay on Invoice, simplified sampling, and the v1.5 sampling kit with lower component costs. Microba GI Navigator, a new category-defining testing product, is on track to launch in October 2026. It is the culmination of several years of leadership at the forefront of this new diagnostic category and represents a meaningful leap in the clinical application of complete microbiome and gut testing. GI Navigator is designed for the Company’s core target patient population, being the significant proportion of people living with an unresolved gastrointestinal disorder, and is a premium product in the category expected to command premium pricing. It is expected to open up the serviceable addressable market to more medical doctors, a significant next segment of the healthcare practitioner market for Microba’s tests. Powered by the Company’s proprietary Clinical Logic Engine, GI Navigator is live with a closed-group early access cohort of opinion-leading practitioners across Australia and the United Kingdom, with the first 35 sales achieved and multiple parts of the product already delivering clinical value and receiving positive feedback. 22 22 OPERATING & FINANCIAL REVIEW SUPPLEMENTS AND INTERNATIONAL PARTNERSHIPS Own-brand Invivo su